Search Results

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.

• Authors : Rosenstock, Julio (); Wysham, Carol (); Frías, Juan P ()

Subjects: TYPE 2 diabetes; GLUCAGON-like peptide-1 agonists; ELI Lilly & Co.MEXICO; INDIA; JAPAN

• Source: Lancet. Jul2021, Vol. 398 Issue 10295, p143-155. 13p.

Record details

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.

• Authors : Davies, Melanie; Færch, Louise; Jeppesen, Ole K

Subjects: TYPE 2 diabetes; WEIGHT loss; OBESITY

• Source: Lancet. 3/13/2021, Vol. 397 Issue 10278, p971-984. 14p.

Record details

Agricola

Record details

Agricola

Record details

Agricola

Record details

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

• Authors : Gather, Alan J.; King, Allen B.; Del Prato, Stefano

Subjects: INSULIN therapy; PEOPLE with diabetes; ANALYSIS of variance

• Source: Lancet. 4/21/2012, Vol. 379 Issue 9825, p1498-1507. 10p.

Record details

Bringing closure: towards achieving a better understanding of Israel.

• Authors : Rosenstock, Julio¹ (AUTHOR) ; Zimmet, Paul² (AUTHOR); Skyler, Jay S³ (AUTHOR)

• Source: Lancet. Aug2019, Vol. 394 Issue 10198, p559-559. 1p.

Record details

Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial.

• Authors : Rosenstock, Julio; Lorber, Daniel L.; Gnudi, Luigi

Subjects: INSULIN therapy administration; DRUG administration; TYPE 2 diabetes treatment

• Source: Lancet. 6/26/2010, Vol. 375 Issue 9733, p2244-2253. 10p. 1 Diagram, 7 Charts, 2 Graphs.

Record details

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

• Authors : Buse, John B.; Rosenstock, Julio; Sesti, Giorgio

Subjects: TYPE 2 diabetes treatment; DRUG efficacy; DRUG dosage

• Source: Lancet. 7/4/2009, Vol. 374 Issue 9683, p39-47. 9p. 1 Diagram, 3 Charts, 3 Graphs.

Record details

Preregistration of study design and non-inferiority margin.

• Authors : van Hateren, Kornelis J. J.; Kleefstra, Nanne; Bilo, Henk J.

Subjects: LETTERS to the editor; DRUG efficacy; TYPE 2 diabetes treatment

• Source: Lancet. 1/12/2013, Vol. 381 Issue 9861, p115-116. 2p.

Record details